← back to search

Wen Yan Zhong

— ·
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies, and Genetic factors in colorectal cancer.
h-index
5
citations
1,129
works
5
NIH funding
primary concept
Medicine
email

Recent publications

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
The Lancet Oncology 2022cited by 872position: middledoi
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
Journal of Clinical Oncology 2022cited by 110position: middledoi
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients
Cancer 2021cited by 69position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yuxian Bai · Harbin Medical University2 papers (2021–2022)Shukui Qin · Affiliated Hospital of Southwest Medical University2 papers (2021–2022) · 1 papers (2022–2022)Shan Zeng · Central South University1 papers (2021–2021)Hyun Cheol Chung · Harbin Medical University1 papers (2021–2021)Jianfeng Li · Henan Forestry Vocational College1 papers (2022–2022)Yu Zhou · Jilin University1 papers (2022–2022)Jianming Xu · University of Technology Sydney1 papers (2021–2021)Tae‐Won Kim · Seoul National University Hospital1 papers (2022–2022)Zhendong Chen · Beijing Computing Center1 papers (2022–2022)Zhendong Chen · Panyu District Central Hospital1 papers (2021–2021)Kangsheng Gu · Jiangnan University1 papers (2021–2021)Xing Ye · Guangzhou University of Chinese Medicine1 papers (2022–2022)Elena Élez · Hôpital Saint-Antoine1 papers (2022–2022)Zhiqiang Meng · Shanghai Medical College of Fudan University1 papers (2022–2022)Juxiang Xiao · First Affiliated Hospital of Xi'an Jiaotong University1 papers (2022–2022)Abby B. Siegel · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2022–2022)Ruocai Xu · Hunan Cancer Hospital1 papers (2022–2022) · 1 papers (2021–2021)Li‐Yuan Bai · China Medical University1 papers (2021–2021)